重复剂量双氢青蒿素-哌喹预防和治疗疟疾的安全性、耐受性和疗效:系统综述与荟萃分析
每月间歇性预防治疗(IPT)用DP相比安慰剂使镜检疟疾寄生虫血症发病率降低84%,且严重不良事件更少;56名IPT-DP接受者QTc间期均在正常范围,未见随疗程增加而显著延长。
要点
- 每月DP用于IPT相比安慰剂降低镜检疟疾寄生虫血症发病率84%。
- 每月IPT-DP的严重不良事件少于安慰剂、每日复方磺胺甲噁唑或每月磺胺多辛-乙胺嘧啶。
- 56名IPT-DP接受者QTc间期均在正常范围,未见随疗程增加显著延长。
核心结论
- 每月DP用于间歇性预防治疗似乎耐受良好且有效。
- 妊娠期需要更多数据,并需进一步探索每月给药的心脏安全性。
研究设计与样本
- 系统综述与荟萃分析,遵循PRISMA指南,于2016年9月1日检索多个数据库。
- 纳入随机对照试验或前瞻性队列研究,涉及重复暴露于标准3天疗程DP用于季节性疟疾化学预防、 масс药物给药或临床疟疾治疗。
- 共纳入11项研究:2项重复治疗研究(1项在5岁以下儿童,1项在孕妇)和9项IPT试验(5项在5岁以下儿童,1项在学龄儿童,1项在成人,2项在孕妇)。
- 采用随机效应荟萃分析生成合并发病率比和相对危险度或风险差。
主要发现
- 每月IPT-DP相比安慰剂与镜检疟疾寄生虫血症发病率降低84%相关。
- 每月IPT-DP相比安慰剂、每日复方磺胺甲噁唑或每月SP与更少严重不良事件相关。
- 56名IPT-DP接受者(26名儿童,30名孕妇)的心脏参数中,所有QTc间期均在正常范围,未见随DP疗程增加而QTc延长显著增加。
关键数值与推荐
- 每月IPT-DP相比安慰剂:镜检疟疾寄生虫血症发病率降低84%。
- 56名IPT-DP接受者(26名儿童,30名孕妇)所有QTc间期均在正常范围,未见随疗程增加显著延长。
临床怎么用
- 每月DP可作为间歇性预防治疗的耐受良好且有效的选择。
- 在妊娠期使用DP进行IPT需更多数据支持。
- 每月给药方案的心脏安全性需进一步探索。
局限性
- 妊娠期数据有限,需要更多研究。
- 每月给药的心脏安全性需进一步探索。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Intermittent preventive treatment (IPT) for malaria is used in infants, children, adults, and pregnant women. Dihydroartemisinin-piperaquine (DP) is an effective, well tolerated artemisinin-based combination therapy. The long half-life of piperaquine makes it attractive for IPT. We conducted a systematic review and meta-analysis to establish the efficacy and safety of repeated treatment with DP. METHODS: Following PRISMA guidelines, we searched multiple databases on Sept 1, 2016, with the terms: "human" AND "dihydroartemisinin-piperaquine" OR "DHA-PPQ". Studies were eligible if they were randomised controlled trials (RCTs) or prospective cohort studies involving repeat exposures to standard 3-day courses of DP for either seasonal malaria chemoprevention, mass drug administration, or treatment of clinical malaria, conducted at any time and in any geographic location. Random-effects meta-analysis was used to generate pooled incidence rate ratios and relative risks, or risk differences. FINDINGS: 11 studies were included: two repeat treatment studies (one in children younger than 5 years and one in pregnant women), and nine IPT trials (five in children younger than 5 years, one in schoolchildren, one in adults, two in pregnant women). Comparator interventions included placebo, artemether-lumefantrine, sulfadoxine-pyrimethamine (SP), SP+amodiaquine, SP+piperaquine, SP+chloroquine, and co-trimoxazole. Of 14 628 participants, 3935 received multiple DP courses (2-18). Monthly IPT-DP was associated with an 84% reduction in the incidence of malaria parasitaemia measured by microscopy compared with placebo. Monthly IPT-DP was associated with fewer serious adverse events than placebo, daily co-trimoxazole, or monthly SP. Among 56 IPT-DP recipients (26 children, 30 pregnant women) with cardiac parameters, all QTc intervals were within normal limits, with no significant increase in QTc prolongation with increasing courses of DP. INTERPRETATION: Monthly DP appears well tolerated and effective for IPT. Additional data are needed in pregnancy and to further explore the cardiac safety with monthly dosing. FUNDING: Bill & Melinda Gates Foundation and NIH.
引用
- Gutman J, Kovacs S, Dorsey G, et al. Safety, tolerability, and efficacy of repeated doses of dihydroartemisinin-piperaquine for prevention and treatment of malaria: a systematic review and meta-analysis. Lancet Infect Dis. 2016. PMID: 27865890. doi:10.1016/S1473-3099(16)30378-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。